Barr Laboratories Articles
Able says first to ship Lithobid generic in USA
28 April 2003
Gedeon Richter sees product mix improve in 2002
21 April 2003
Cephalon files patent suits over generic Provigil
7 April 2003
Barr's generic Adderall cleared in USA
31 March 2003
Barr
3 February 2003
Barr Labs raises 2nd-qtr earnings forecast
20 January 2003
Shire hit by Adderall XR patent challenge
13 January 2003
Ranbaxy gets OK for generic Adderall
1 July 2002
Eon gets OK for 2nd generic of Adderall
24 June 2002
Barr Labs' extended-release lithium is FDA-approved
17 June 2002
Barr gets OK for generic Nordette in USA
3 June 2002
Generic success sparks further competition
20 May 2002
Barr to file novel OC in mid-2002
13 May 2002
Barr Labs being sued by Organon, Shire
13 May 2002
Revenues in 1st-qtr rise 30% at Shire
6 May 2002
Barr gets US OK for Mircette generic
15 April 2002
Barr's generic Levlite OKed in USA
8 April 2002
Barr to acquire Enhance Pharma in $44M deal
1 April 2002
Barr/Natural Biologics to develop generic Premarin
11 March 2002
Barr gets US OK for generic Adderall
18 February 2002
Barr and Aventis file suit over Allegra-D patents
4 February 2002
Barr second-quarter earnings leap on sales of generic Prozac
4 February 2002
Barr to launch Dexedrine Spansule generic in Feb?
28 January 2002
Barr Labs raises 2002 earnings estimates
7 December 2001
Blow for Shire as Barr predicts early approval for generic Adderall
29 November 2001
Barr gets go-ahead for tuberculosis generic
28 November 2001
Stock Commentary - New York
15 November 2001
Aventis growth driven by strong US pharmaceutical sales
6 November 2001
Bayer paid $200M to keep generic Cipro off market, says lawsuit
31 October 2001
Merck sues Teva over generic alendronate
8 October 2001
Biovail files NDA for quick-melt fluoxetine
3 October 2001
Barr plans stock buyback
20 September 2001
Generic flutamide reaches US market
20 September 2001
Barr gets tentative OK for 10mg Prozac tabs
6 September 2001
Barr's entitlement to tamoxifen exclusivity questioned
29 August 2001
Stock Commentary - New York
9 August 2001
Barr set to launch generic Prozac in USA?
2 August 2001
New drugs lift Lilly's 2nd qtr sales 16%
23 July 2001
New drugs lift Lilly's 2nd qtr sales 16%
20 July 2001
Barr Labs increases earnings estimate
12 July 2001
Barr acquires Duramed - UPDATE
2 July 2001
180-day exclusivity for Teva's famotidine
6 June 2001
Pharma Res to market generic Prozac
1 June 2001
Florida Senate votes to allow generics
4 May 2001
Tentative approval for Barr's generic contraceptive
15 March 2001
New directors at Barr
1 March 2001
Lilly faces first generic challenge to Zyprexa
26 February 2001
Barr Labs sees last qtr 2000 earnings up 33%
16 February 2001
Barr's generic Luvox approved
29 January 2001
Stock Commentary New York
17 August 2000
Barr mounts challenge to Ortho contraceptive in USA
15 June 2000
Barr takes on Prozac 10mg tablets in USA
5 June 2000
Florida progresses bill to boost generics
18 April 2000
Healthy full-year results for many US pharmaceutical companies
27 January 2000
Barr & DuPont set up marketing pact
21 January 2000
Henney reassures on generic drugs
8 December 1999
Management changes at Barr Labs
2 December 1999
Appointments at Barr Labs
4 November 1999
Senate interim health/aging report slams Florida State Negative Drug
14 September 1999
Texas BoP rejects curbs on generics
18 August 1999
AZ, Barr tamoxifen deal probed again
1 July 1999
Barr looking to quadruple EPS by 2003
3 June 1999
Stock Commentary New York
13 May 1999
FDA confirms Barr Laboratories' generic tamoxifen right
11 March 1999
DuPont has "poisoned" generic climate, says Barr
3 February 1999
Lilly paying $4 million to settle Prozac case
27 January 1999
Lilly's Prozac case with Barr Labs begins
25 January 1999
US Justice Dept probes tamoxifen price
14 January 1999
Phase III for emergency contraceptive
21 December 1998
Lilly Focusing On Core Business, Prozac Case Looms
20 November 1998
Nolvadex Approval Puts Zeneca On A High
19 November 1998
Zeneca's Nolvadex Approval From US FDA
2 November 1998
Stock Commentary New York
10 September 1998
Loss Per Share Narrows At Warner Chilcott
8 May 1998
Barr Sues DuPont Merck Over Warfarin
11 March 1998
Drug Cos Must Act Now To Ensure Future Prosperity
22 January 1998
Coumadin Battle Ends?
20 November 1997
Net Earnings Quadruple At Barr
6 November 1997
Barr Labs Launches First Generic Warfarin In USA
31 July 1997
IPO For Warner Chilcott
17 July 1997
FDA Rejects Generic Premarin Challenge
12 May 1997
Significant Increases For US Drug Firms In 1996
3 February 1997
Bayer/Barr Settlement
27 January 1997
Barr & Wyeth Ayerst's Premarin Battle
25 November 1996
US Quarterly Results Show Improvements
4 November 1996
Promotions At Barr Laboratories
28 October 1996
Assessing The Worldwide Market For Generics
28 October 1996
Record Sales For Barr Laboratories
9 September 1996
Barr Laboratories Receive US FDA Approval For Danazol
19 August 1996
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
